search
Back to results

The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria (SUPERIOR)

Primary Purpose

Coronary Artery Disease

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Intravascular imaging
Sponsored by
CardioNavi MedTech (Wuhan) Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Artery Disease focused on measuring Intravascular imaging, Intravascular ultrasound, Optical coherence tomography

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subject must be at least 18 years of age and less than 85 years of age.
  2. Subject must be informed and sign a written consent
  3. Subject must have evidence of myocardial ischemia, unstable angina or acute myocardial infarction suitable for PCI.

Exclusion Criteria:

  1. Women who are pregnant or cannot eliminate the possibility to be pregnant.
  2. Estimated creatinine clearance <30 ml/min/1.73 m2 using Cockcroft equation.
  3. LVEF(Left ventricular ejection fraction) < 35% by the most recent imaging test within 7 days prior to procedure.
  4. Unstable ventricular arrhythmias.
  5. High bleeding risk, active peptic ulcers or cerebrovascular accident or transient ischemic attack within the past 6 months.
  6. Known contraindication to anticoagulants and antiplatelets therapy.
  7. Known hypersensitivity to aspirin, clopidogrel, heparin, iodinated contrast, ticagrelor, bivalirudin, metal materials in stent.
  8. Any intervention for not target vessel within 48 hours after the study procedure.
  9. Any conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation.

Angiographic exclusion criteria:

  1. The reference diameter of target vessel is less than 2.5 mm.
  2. The target lesion involves myocardial bridge.
  3. The target lesion is in the left main coronary artery or the damage is observed in the ostium.
  4. Severe calcification in the target vessel.
  5. Severe tortuosity in the target vessel.
  6. Multiple contiguous stent implantation in the target vessel.
  7. Subject has coronary artery spasm.
  8. In-stent restenosis.
  9. Any study lesion characteristic that, in the investigator's opinion, is not available for intravascular imaging.

Sites / Locations

  • Beijing Anzhen Hospital, Capital Medical UniversityRecruiting
  • Beijing Tiantan Hospital, Capital Medical University
  • Chinese PLA General HospitalRecruiting
  • Peking University Third HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Novasight IVUS/OCT

Arm Description

A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter

Outcomes

Primary Outcome Measures

Clear image length measured by Core lab
The clear image length is transformed from the clear image frame, and the ratio of the clear image can be calculated by Clear image length / Full image length * 100%

Secondary Outcome Measures

Catheter-related major adverse events
Cardiac death, myocardial infarction, blood-limited dissection
Clear stent length measured by Core lab
Clear stent length is defined as the total stent length visualized within the clear image length.
Device Success
Successfully deliver the catheter to the target lesion and withdrawal without fracture
Technical Success
Successfully imaging
Image quality evaluated by operator
Objective and subjective assessment of image quality.
System reliability evaluated by operator
Objective and subjective assessment of system reliability.
Catheter operability evaluated by operator
Objective and subjective assessment of catheter operability.

Full Information

First Posted
October 21, 2020
Last Updated
May 28, 2021
Sponsor
CardioNavi MedTech (Wuhan) Co., Ltd.
Collaborators
Beijing Jingruitianhe Medical Science and Technology Development Co,Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT04617899
Brief Title
The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria
Acronym
SUPERIOR
Official Title
The Study to Evaluate the Performance and Safety of the Novasight Hybrid System Using Objective Performance Criteria
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 17, 2021 (Actual)
Primary Completion Date
November 30, 2021 (Anticipated)
Study Completion Date
December 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CardioNavi MedTech (Wuhan) Co., Ltd.
Collaborators
Beijing Jingruitianhe Medical Science and Technology Development Co,Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This prospective, multicenter, single-arm study aims to evaluate the safety, operability and practicability of the novel hybrid intravascular imaging system/catheter during the percutaneous transluminal coronary intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Intravascular imaging, Intravascular ultrasound, Optical coherence tomography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Novasight IVUS/OCT
Arm Type
Experimental
Arm Description
A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter
Intervention Type
Diagnostic Test
Intervention Name(s)
Intravascular imaging
Intervention Description
Use of imaging catheter
Primary Outcome Measure Information:
Title
Clear image length measured by Core lab
Description
The clear image length is transformed from the clear image frame, and the ratio of the clear image can be calculated by Clear image length / Full image length * 100%
Time Frame
During the procedure
Secondary Outcome Measure Information:
Title
Catheter-related major adverse events
Description
Cardiac death, myocardial infarction, blood-limited dissection
Time Frame
Periprocedure
Title
Clear stent length measured by Core lab
Description
Clear stent length is defined as the total stent length visualized within the clear image length.
Time Frame
During the procedure
Title
Device Success
Description
Successfully deliver the catheter to the target lesion and withdrawal without fracture
Time Frame
During the procedure
Title
Technical Success
Description
Successfully imaging
Time Frame
During the procedure
Title
Image quality evaluated by operator
Description
Objective and subjective assessment of image quality.
Time Frame
During the procedure
Title
System reliability evaluated by operator
Description
Objective and subjective assessment of system reliability.
Time Frame
During the procedure
Title
Catheter operability evaluated by operator
Description
Objective and subjective assessment of catheter operability.
Time Frame
During the procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject must be at least 18 years of age and less than 85 years of age. Subject must be informed and sign a written consent Subject must have evidence of myocardial ischemia, unstable angina or acute myocardial infarction suitable for PCI. Exclusion Criteria: Women who are pregnant or cannot eliminate the possibility to be pregnant. Estimated creatinine clearance <30 ml/min/1.73 m2 using Cockcroft equation. LVEF(Left ventricular ejection fraction) < 35% by the most recent imaging test within 7 days prior to procedure. Unstable ventricular arrhythmias. High bleeding risk, active peptic ulcers or cerebrovascular accident or transient ischemic attack within the past 6 months. Known contraindication to anticoagulants and antiplatelets therapy. Known hypersensitivity to aspirin, clopidogrel, heparin, iodinated contrast, ticagrelor, bivalirudin, metal materials in stent. Any intervention for not target vessel within 48 hours after the study procedure. Any conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation. Angiographic exclusion criteria: The reference diameter of target vessel is less than 2.5 mm. The target lesion involves myocardial bridge. The target lesion is in the left main coronary artery or the damage is observed in the ostium. Severe calcification in the target vessel. Severe tortuosity in the target vessel. Multiple contiguous stent implantation in the target vessel. Subject has coronary artery spasm. In-stent restenosis. Any study lesion characteristic that, in the investigator's opinion, is not available for intravascular imaging.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Muyan Zou
Phone
0086-15564579827
Email
zoumuyan@qq.com
Facility Information:
Facility Name
Beijing Anzhen Hospital, Capital Medical University
City
Beijing
State/Province
Chaoyang District
ZIP/Postal Code
100029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong Zeng, Dr.
Facility Name
Beijing Tiantan Hospital, Capital Medical University
City
Beijing
State/Province
Fengtai District
ZIP/Postal Code
100050
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Haidian District
ZIP/Postal Code
100039
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jing Jing, Dr.
First Name & Middle Initial & Last Name & Degree
Yundai Chen, Professor
Facility Name
Peking University Third Hospital
City
Beijing
State/Province
Haidian District
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yida Tang, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
According to the policy of the Human Genetic Resource Administration of China, the data is limited and it could not be shared currently.

Learn more about this trial

The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria

We'll reach out to this number within 24 hrs